Imatinib Mesylate

Form: Tablet

Strength: 50 mg, 100 mg, 400 mg

Reference Brands: Gleevec® (EU & US)

Category: Oncology Cancer Care

Imatinib Mesylate is a targeted therapy used in oncology to treat chronic myeloid leukemia (CML), gastrointestinal stromal tumors (GISTs), and other cancers. Available under the brand Gleevec® by Novartis and as generics, Imatinib is an essential tyrosine kinase inhibitor (TKI) used in cancer centers, hospitals, and oncology clinics. It blocks the action of abnormal proteins that contribute to cancer cell growth, making it crucial for effective cancer management. Available in oral tablets and generics, Imatinib Mesylate is widely sourced by B2B pharmaceutical wholesalers in the US and EU, ensuring reliable supply and GMP-compliant distribution for cancer treatment.